Enhertu Granted Priority Review in the US for Patients with HER2-Low Metastatic Breast Cancer

AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application of Enhertu for the treatment of adult patients in the US with unresectable or metastatic HER2-low breast cancer who have received a prior therapy in the metastatic setting.